Emtricitabine and tenofovir disoproxil fumarate

A comprehensive new industry report analyzes over 1,670 clinical-stage partnering agreements in pharma and biotech from 2020-2025, providing unprecedented access to deal structures and financial terms.

Gilead Sciences has settled a significant patent dispute with ViiV Healthcare, agreeing to pay $1.25 billion plus ongoing royalties on Biktarvy sales until 2027, resolving litigation dating back to 2018.

Quebec becomes the first Canadian province to provide public reimbursement for APRETUDE, a long-acting injectable HIV prevention drug, through RAMQ coverage for at-risk individuals.

The recent USAID stop-work order has halted critical HIV research and treatment programs in Nigeria and Uganda, affecting millions of patients who depend on aid-funded antiretroviral therapy.

Janssen and ViiV Healthcare have reported positive phase III trial results for their once-monthly injectable HIV treatment, combining cabotegravir and Edurant. This innovative regimen could significantly reduce the treatment burden from daily pills to just 12 injections per year, with comparable efficacy to current oral therapies. The findings, presented at the Conference on Retroviruses and Opportunistic Infections, highlight a potential paradigm shift in HIV treatment.